The Zacks Analyst Blog Highlights: UBS, Celgene, Sanofi, Roche and Eli Lilly

 The Zacks Analyst Blog Highlights: UBS, Celgene, Sanofi, Roche and Eli Lilly

PR Newswire

CHICAGO, Oct. 24, 2012

CHICAGO, Oct. 24, 2012 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include UBS AG (NYSE:UBS), Celgene
Corporation (Nasdaq:CELG), Sanofi (NYSE:SNY), Roche (OTC:RHHBY) and Eli Lilly
and Company (NYSE:LLY).


Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter:

Here are highlights from Tuesday's Analyst Blog:

UBS Plans More Layoffs

UBS AG (NYSE:UBS) is contemplating more layoffs in the European investment
banking division, according to a Bloomberg report. The job cuts come as part
of the company's efforts to reorganize its business.

The layoffs are now likely to be in the equities and fixed income section as
the company resizes its merger advisory business, according to the report.
This would result in total job cuts of around 400. The layoffs represent
around 10% of the division's front office staff in the region.

Only last month, according to a Bloomberg report, around 80 to 90 jobs were
planned to be slashed at UBS advisory division, which comprises equity and
debt capital markets. The layoffs are expected to spill over to the trading
business too.

The layoffs come as UBS faces a challenging operating environment in the
region. The sovereign debt crisis has been a matter of concern and the company
has resorted to such restructuring measures to address such issues. Notably,
the company, which is trimming its securities division to refocus on its
wealth management business, has already achieved its target of employee
reductions it scheduled for the end of next year.

UBS, which is scheduled to report its earnings later this month, is not the
only European firm that is overhauling its business. Amidst the stressed
operating environment and stringent capital norms, other European firms are
rightsizing their business to meet such challenges.

FDA Label Expansion for Abraxane

Celgene Corporation (Nasdaq:CELG) announced that it has received approval from
the US Food and Drug Administration (FDA) for a label expansion of its cancer
drug, Abraxane.

Celgene gained approval to use Abraxane as a first-line combination therapy
for treating patients suffering from locally advanced or metastatic non-small
cell lung cancer (NSCLC). Curative surgery or radiation therapy is not
applicable for those patients.

The FDA approval of Abraxane for the additional indication was based on
positive results from a phase III study (CA-031). We note that Abraxane is
already available in the US as a second-line therapy for metastatic breast
cancer. Approval for the new indication has boosted Abraxane's sales

The NSCLC market is highly crowded and includes players, such as Sanofi
(NYSE:SNY), Roche (OTC:RHHBY) and Eli Lilly and Company (NYSE:LLY).

We note that Celgene is also seeking approval for the NSCLC indication in
Japan, Australia and New Zealand. The regulatory authorities in those
countries are expected to decide on the matter in 2013.

Moreover, Abraxane is being developed for other indications, such as
metastatic pancreatic cancer (phase III MPACT study, data expected by
year-end/the first quarter of 2013).

We note that an eagerly awaited event at Celgene concerns its oncology
candidate, pomalidomide. Celgene is seeking approval of the candidate in
combination with low-dose dexamethasone for the treatment of relapsed and
refractory multiple myeloma patients, who have received at least two prior
therapies. A final decision from the FDA is expected by February 10, 2013
(action date).

Our Recommendation

We currently have a Neutral recommendation on Celgene. The stock carries a
Zacks #3 Rank (Hold rating) in the short run.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.